

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		Atty. Docket No.: 7570/80968	Appl. No.: 10/772,089
		Applicant(s) Farzan, <i>et al.</i>	
		Filing Date: February 5, 2004	Group: to be assigned 1648
Examiner Initial			
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)			
2	C 1	BERGER, "HIV Entry and Tropism: The Chemokine Receptor Connection," <i>AIDS 11(Supp. A):S3-S16</i> (1997).	
	C 2	COLE, <i>et al.</i> , "Characterization of Neutralization Epitopes of Simian Immunodeficiency Virus (SIV) Recognized by Rhesus Monoclonal Antibodies Derived from Monkeys Infected with an Attenuated SIV Strain," <i>Virology</i> 290:59-73 (2001).	
	C 3	CORMIER, <i>et al.</i> , "Specific Interaction of CCR5 Amino-Terminal Domain Peptides Containing Sulfotyrosines with HIV-1 Envelope Glycoprotein gp120," <i>Proc. Natl. Acad. Sci. USA</i> 97:5762-5767 (2000).	
	C 4	DENG, <i>et al.</i> , "Identification of a Major Co-Receptor for Primary Isolates of HIV-1," <i>Nature</i> 381:661-666 (1996).	
	C 5	DORANZ, <i>et al.</i> , "Chemokine Receptors as Fusion Cofactors for Human Immunodeficiency Virus Type 1 (HIV-1)," <i>Immunologic Research</i> 16:15-28 (1997).	
	C 6	DRAGIC, <i>et al.</i> , "HIV-1 Entry into CDR ⁺ Cells Is Mediated by the Chemokine Receptor CC-CKR-5," <i>Nature</i> 381:667-673 (1996).	
	C 7	FARZAN, <i>et al.</i> , "A Tyrosine-Rich Region in the N Terminus of CCR5 Is Important for Human Immunodeficiency Virus Type 1 Entry and Mediates an Association between gp120 and CCR5," <i>J. Virol.</i> 72:1160-1164 (1998).	
	C 8	FARZAN, <i>et al.</i> , "Tyrosine Sulfation of the Amino Terminus of CCR5 Facilitates HIV-1 Entry," <i>Cell</i> 96:667-676 (1999).	
	C 9	FARZAN, <i>et al.</i> , "A Tyrosine-Sulfated Peptide Based on the N Terminus of CCR5 Interacts with a CD4-Enhanced Epitope of the HIV-1 gp120 Envelope Glycoprotein and Inhibits HIV-1 Entry," <i>J. Biol. Chem.</i> 275:33516-33521 (2000).	
	C 10	FOUTS, <i>et al.</i> , "Neutralization of the Human Immunodeficiency Virus Type 1 Primary Isolate JR-FL by Human Monoclonal Antibodies Correlates with Antibody Binding to the Oligomeric Form of the Envelope Glycoprotein Complex," <i>J. Virol.</i> 71:2779-2785 (1997).	
3	C 11	HO, <i>et al.</i> , "Conformational Epitope on gp120 Important in CD4 Binding and Human Immunodeficiency Virus Type 1 Neutralization Identified by a Human Monoclonal Antibody," <i>J. Virol.</i> 65:489-493 (1991).	
	C 12		
	C 13		
	C 14		
	C 15		
	C 16		
	C 17		
	C 18		
Examiner		Date Considered 06/25/07	

PTO/SB/08a
Substitute for Form 1449A/PTC

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---


Application Number	10/772,089
Filing Date	February 5, 2004
First Named Inventor	FARZAN et al.
Art Unit	1814 1648
Examiner Name	IBA PARKER, JEFFREY
Attorney Docket	7570/80968

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	06/25/07
--------------------	---	-----------------	----------

Draw line through citation if not in compliance with MPER 609

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 1 Applicant's unique citation designation number (optional). 2 See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.
 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

